Disclosures: The authors report no relevant financial disclosures.
August 31, 2021
1 min read
Save

Prevalence of elevated FeNO, peripheral eosinophilia higher in patients with COPD, asthma

Disclosures: The authors report no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients with COPD and a history of asthma had a higher prevalence of elevated fractional exhaled nitric oxide levels compared with patients with COPD and no asthma history, according to new data published in Thorax.

“Our study supports clinically phenotyping COPD subjects with eosinophilic inflammation be independent of their asthma history and peripheral eosinophilia can be used as a surrogate marker in resource-limited settings,” Srinadh Annangi, MD, pulmonologist in the department of pulmonary critical care and sleep medicine at University of Kentucky College of Medicine, Lexington, and colleagues wrote.

Adults with a history of COPD and asthma had a higher prevalence for elevated FeNO and peripheral eosinophilia compared with those with no COPD or asthma history. Data were derived from Annangi S, et al. Thorax. 2021;doi:10.1136/thoraxjnl-2020-214644.

Researchers analyzed data from the National Health and Nutrition Examination Survey from 2007 to 2010 on 3,110,617 patients (mean age, 59.3 years; 64.4% men) with COPD and a postbronchodilator FEV1/FVC ratio less than 0.7. The researchers categorized patients with COPD into groups based on history of asthma (n = 2,655,739) or no history (n = 454,878).

In the cohort of patients with COPD, the overall prevalence of asthma history was 14.6%. The overall prevalence of peripheral eosinophilia was 36% (38.3% in patients with COPD and asthma; 35.6% in patients with COPD and no asthma history; P < .001).

The prevalence of FeNO 25 parts per billion was 14.3%; the prevalence was 28.7% in patients with COPD and a history of asthma and 13% in those with COPD without a history of asthma. Researchers observed significantly higher mean FeNO levels among patients with COPD and asthma history compared with those without asthma history (19.6 ppb vs. 15.8 ppb; P < .001).